Background: Most patients with advanced-stage indolent non-Hodgkin lymphoma have multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory indolent non-Hodgkin lymphoma., Methods: ZUMA-5 is a single-arm, multicentre, phase 2 trial being conducted at 15 medical cancer centres in the USA and two medical cancer centres in France. Patients were eligible if they were aged 18 years or older, with histologically confirmed indolent non-Hodgkin lymphoma (follicular lymphoma or marginal zone lymphoma), had relapsed or refractory disease, previously had two or more lines of therapy (including an anti-CD20 monoclonal antibody with an alkylating agent), and an Eastern Cooperative Oncology Group performance score of 0 or 1. Patients underwent leukapheresis and received conditioning chemotherapy (cyclophosphamide at 500 mg/m 2 per day and fludarabine at 30 mg/m 2 per day on days -5, -4, and -3) followed by a single infusion of axicabtagene ciloleucel (2 × 10 6 CAR T cells per kg) on day 0. The primary endpoint was overall response rate (complete response and partial response) assessed by an independent review committee per Lugano classification. The primary activity analysis was done after at least 80 treated patients with follicular lymphoma had been followed up for at least 12 months after the first response assessment at week 4 after infusion. The primary analyses were done in the per-protocol population (ie, eligible patients with follicular lymphoma who had 12 months of follow-up after the first response assessment and eligible patients with marginal zone lymphoma who had at least 4 weeks of follow-up after infusion of axicabtagene ciloleucel). Safety analyses were done in patients who received an infusion of axicabtagene ciloleucel. This study is registered with ClinicalTrials.gov, NCT03105336, and is closed to accrual., Findings: Between June 20, 2017, and July 16, 2020, 153 patients were enrolled and underwent leukapheresis, and axicabtagene ciloleucel was successfully manufactured for all enrolled patients. As of data cutoff (Sept 14, 2020), 148 patients had received an infusion of axicabtagene ciloleucel (124 [84%] who had follicular lymphoma and 24 [16%] who had marginal zone lymphoma). The median follow-up for the primary analysis was 17·5 months (IQR 14·1-22·6). Among patients who were eligible for the primary analysis (n=104, of whom 84 had follicular lymphoma and 20 had marginal zone lymphoma), 96 (92%; 95% CI 85-97) had an overall response and 77 (74%) had a complete response. The most common grade 3 or worse adverse events were cytopenias (104 [70%] of 148 patients) and infections (26 [18%]). Grade 3 or worse cytokine release syndrome occurred in ten (7%) patients and grade 3 or 4 neurological events occurred in 28 (19%) patients. Serious adverse events (any grade) occurred in 74 (50%) patients. Deaths due to adverse events occurred in four (3%) patients, one of which was deemed to be treatment-related (multisystem organ failure)., Interpretation: Axicabtagene ciloleucel showed high rates of durable responses and had a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma., Funding: Kite, a Gilead Company., Competing Interests: Declaration of interests CAJ has received support for the present manuscript from Kite, a Gilead Company; has received consulting fees from Novartis, Bristol-Myers Squibb, Precision Biosciences, Nkarta, Bluebird Bio, AbbVie, Lonza, and Ipsen; and has received payment or honoraria from Novartis, Bristol-Myers Squibb, Bluebird Bio, and Epizyme. JCC reports consulting fees from Novartis Kite, a Gilead Company, AbbVie, Janssen, ADC Therapeutics, and Karyoplasm, and payment or honoraria from Morphosys, BeiGene, Epizyme, Bristol-Myers Squibb, and AstraZeneca. ARS reports support to their institution from Kite, a Gilead Company for the present manuscript and clinical trial support from Bristol-Myers Squibb. BMW reports consulting fees for an advisory board from Bristol-Myers Squibb. JM has received consulting fees from AbbVie, Bayer, Kite, a Gilead Company, Pfizer, Janssen, Bristol-Myers Squibb, Kyowa, Alexion, Fosunkite, Innovent, SeaGen, Debiopharm, Karyopharm, Genmab, ADC Therapeutics, Epizyme, BeiGene, and Servier; honoraria from Targeted Oncology, OncView, Curio Sciences, Kyowa, Physicians' Education Resource, and SeaGen; honoraria for speaker's bureaus from Kite, a Gilead Company, Kyowa, Bayer, Janssen, SeaGen, Acrotech/Aurobindo, BeiGene, Verastem, AstraZeneca, Bristol-Myers Squibb, and Genentech/Roche; and research funding from Bayer, Kite, a Gilead Company, Bristol-Myers Squibb, Merck, Portola, Incyte, Genentech, Pharmacyclics, SeaGen, Janssen, and Millennium. GS reports support from Kite, a Gilead Company for the present manuscript; consulting fees from Bristol-Myers Squibb, Incyte, Ipsen, Janssen, Kite, a Gilead Company, Loxo, Lilly, Milteniy, Morphosys, Novartis, and Rapt; payment or honoraria from AbbVie, Amgen, Bayer, Epizyme, Regeneron, Roche, Morphosys, Kite, a Gilead Company, and Novartis; and participation on a data safety monitoring board or advisory board at AbbVie, Beigene, Bristol-Myers Squibb, Debiopharm, Epizyme, Genentech/Roche, Genmab, Incyte, Kite, a Gilead Company, Milteniy, Morphosys, Takeda, and Velosbio. PNM reports payment or honoraria for a speaker's bureau from Kite, a Gilead Company and Incyte, and stock or stock options from Amgen. CC reports research funding from Veristem, Gilead, Bristol-Myers Squibb, and Genentech. DGM reports research funding from Bristol-Myers Squib and Kite, a Gilead Company; rights to royalties from Fred Hutch for patents licensed to Bristol-Myers Squibb; honoraria for advisory boards from Amgen, Bristol-Myers Squibb, Genentech, Gilead Sciences, Incyte, Janssen, Kite, a Gilead Company, Legend Biotech, MorphoSys, Mustang Bio, Novartis, Pharmacyclics, and Umoja; has participated on a data safety monitoring board or steering committee for Bioline RX, Bristol-Myers Squibb, and Genentech; has held a leadership role at Bristol-Myers Squibb and Genentech; and has had honoraria and stock options from A2 Biotherapeutics and Navan Technologies, Inc. SdV has participated on an advisory board with BeiGene. RR reports support from Gilead for the present manuscript; consulting fees from Gilead, Novartis, Bristol-Myers Squibb, Synthekine, TScan, Regeneron, and Atara; payment for expert testimony for Bayer; travel and meeting support from Gilead; and participation on a data safety monitoring board or advisory board at the University of Pennsylvania. LAL has received consulting fees from AbbVie, AstraZeneca, Merck, TG Therapeutics, Janssen, Epizyme, Kite, a Gilead Company, and Bristol-Myers Squibb; has received payment or honoraria for speaker's bureaus from Kite, a Gilead Company, Beigene, Janssen, AstraZeneca, SeaGen, TG therapeutics, Epizyme, Karyopharm; has participated on advisory boards with TG therapeutics, AbbVie, Janssen, AstraZeneca, SeaGen, ADC Therapeutics; and has a leadership role at the Leukemia/lymphoma Society and the Lymphoma Research Foundation. IY-A has received consulting fees from Kite, a Gilead Company and Novartis; payment or honoraria from Bristol-Myers Squibb, Janssen, and Kite, a Gilead Company; and meeting and travel support from Kite, a Gilead Company. OOO reports consulting fees from Kite, a Gilead Company, Pfizer, Novartis, and Janssen, and honoraria from Kite, a Gilead Company. HCHF has received consulting fees from Pfizer, Genzyme, BeiGene, Jazz pharmaceuticals, and Alexion, and has received payment or honoraria for speaker's bureaus and lectures from Bristol-Myers Squibb, AstraZeneca, Janssen, karyopharm, Kite, a Gilead Company, Takeda, Amgen, AbbVie, and Genentech. JR reports support for the current manuscript from Kite, a Gilead Company; grants from Synergys and Biograph55; planned patents with Synergys; leadership at the American Association for Cancer Research, American Society of Hematology, and the American Society of Clinical Oncology, and stock options with ISK. JMR reports employment with Kite, a Gilead Company and equity ownership in Kite, a Gilead Company in support of the present manuscript. LG and RV report employment with and equity ownership with Kite, a Gilead Company. VP reports travel and meeting support from Kite, a Gilead Company and equity ownership in Gilead. MPA reports employment with Kite, a Gilead Company and equity ownership in Gilead. SSN reports support from Kite, a Gilead Company for the present manuscript; grants or contracts from Kite, a Gilead Company, Merck, Bristol-Myers Squibb, Cellectis, Poseida, Karus, AstraZeneca, Allogene, Unum Therapeutics, Precision Biosciences, and Adicet Bio; royalties from Takeda; consulting fees from Kite, a Gilead Company, Merck, Bristol-Myers Squibb, Novartis, Unum Therapeutics, Pfizer, Precision Biosciences, Cell Medica/Kuur, Allogene, Incyte, Legend Biotech, Adicet Bio, Calibr, and Bluebird Bio; payment or honoraria from Medscape, Aptitude Health, Bio Ascend, and MJH Life Sciences; and patents pending related to cell therapy. YY declares no competing interests., (Copyright © 2022 Elsevier Ltd. All rights reserved.)